- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07613047
Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix
A Prospective, Double-Arm, Randomized Controlled Trial Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix Compared to Resorbable Collagen Membranes in Edentulous Ridge Augmentation
Panoramica dello studio
Stato
Descrizione dettagliata
This investigator-initiated study will compare ADM and resorbable collagen membrane barrier for guided bone regeneration. Systematic reviews and randomized clinical trials confirm that resorbable collagen membranes combined with particulate graft materials predictably increase horizontal ridge width, typically achieving gains of approximately 3-5 mm at 6 months.3,5 The biologic mechanism involves clot stabilization, space maintenance (often supported with fixation tacks or tenting screws), and exclusion of competing soft tissue cells.3 Despite these predictable outcomes, collagen membranes possess inherent limitations, including limited intrinsic structural rigidity, susceptibility to enzymatic degradation when exposed6 and lack of contribution to gingival phenotype modification.
In contrast, human data evaluating acellular dermal matrix (ADM) as a barrier membrane in horizontal guided bone regeneration is limited. One of the earliest clinical and histologic investigations evaluated ADM in the management of Seibert Class I horizontal ridge defects using particulate grafting and reported both clinical ridge width improvement and histologic evidence of new vital bone formation.12 Notably, the authors also observed increased soft tissue thickness at treated sites, suggesting a potential dual hard- and soft-tissue benefit for its use. However, this study was a single-arm design without a direct comparator group, limiting the ability to determine whether outcomes were equivalent or superior to those achieved with conventional collagen membranes.
The majority of human ADM literature focuses on periodontal plastic surgery applications rather than GBR, including tooth root coverage procedures to treat gingival recession,10 peri-implant soft tissue augmentation,15 and keratinized tissue (KT) augmentation techniques.16 These investigations consistently demonstrate increased mucosal thickness and KT width with ADM use, reinforcing its soft tissue regenerative capacity. Nevertheless, these outcomes cannot be extrapolated directly to horizontal ridge augmentation without controlled comparative data.
Preclinical animal studies provide additional biologic rationale. It has been demonstrated in a canine GBR model that ADM functioned as an effective barrier membrane, with histologic evidence of new bone formation comparable to bioabsorbable membranes.17 Additional animal studies have shown that ADM supports vascular infiltration, integrates into host tissues, and maintains an acceptable inflammatory profile during early healing.18 Histomorphometric analyses in these models report woven bone formation beneath ADM at early intervals, followed by progressive remodeling into lamellar bone. While these findings support the biologic plausibility of ADM as a GBR membrane, animal data cannot substitute for controlled human clinical trials.16-19 Importantly, no adequately powered human randomized controlled trial has directly compared ADM and resorbable cross-linked collagen membranes head-to-head in horizontal ridge augmentation with GBR using standardized volumetric CBCT analysis, histomorphometric evaluation of post-healing bone biopsy, and longitudinal soft tissue assessment. Existing studies either evaluate collagen membranes alone,3,5 assess ADM in non-comparative design,12 or evaluate ADM and other autogenous, xenogeneic, or allogeneic soft tissue grafts for phenotype modification without simultaneous GBR.10,14,15 Consequently, it remains unclear whether ADM provides equivalent bone volume augmentation, histologic bone formation, and if it confers additional soft tissue benefits in the context of ridge augmentation, or whether its clinical performance differs in the setting of membrane exposure.
This absence of direct comparative human data represents a critical gap in the literature and provides the rationale for a randomized controlled trial evaluating ADM versus resorbable collagen membranes in horizontal guided bone regeneration.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Sarah Startley, DMD
- Numero di telefono: 205-975-8711
- Email: ss1971@uab.edu
Backup dei contatti dello studio
- Nome: Maria Geisinger, DDS, MS
- Numero di telefono: 205-934-4984
- Email: miagdds@uab.edu
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- University of Alabama at Birmingham
-
Contatto:
- Sarah Startley, DMD
- Numero di telefono: 205-975-8711
- Email: ss1971@uab.edu
-
Contatto:
- Maria Geisinger, DDS, MS
- Numero di telefono: 205-934-4984
- Email: miagdds@uab.edu
-
Investigatore principale:
- Maria Geisinger, DDS, MS
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- English speaking
- At least 18 years old
- Must be a patient of the UAB Dental School
- Able to read and understand informed consent document
- Patients presenting with a diagnosed need horizontal ridge augmentation with GBR without simultaneous implant placement, to allow for future dental implant placement.
- Presence of periodontally healthy, non-carious neighboring teeth and/or healthy restored dental implants on either side of the edentulous span planned for GBR, or unhealthy adjacent teeth to be extracted during the same visit.
- ≤4 mm ridge width in a Seibert Class I Edentulous span19
- No anticipated need for surgical and/or endodontic care at planned teeth adjacent to the proposed surgical site during the study period.
Exclusion Criteria:
- Non-English speaking
- Less than 18 years old
- Smokers/nicotine users (defined as currently reporting use of any form of tobacco/nicotine products)
Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing, including:
- Uncontrolled diabetes (HbA1c > 7%)
- Untreated periodontal disease
- History of head/neck radiation
- IV bisphosphonates
- Immunocompromised state
- Pregnancy
- Acute infection at site
- Documented or suspected allergy or sensitivity to any study product
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Guided Bone Regeneration with ADM (AlloDerm) as a barrier
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture.
Following decortication and graft placement to reconstruct the horizontal ridge deficiency, acellular dermal matrix (ADM) will be adapted to fully cover the augmented site with appropriate extension beyond the defect margins.
The ADM will be stabilized using titanium tacks and/or periosteal sutures as needed to ensure space maintenance and membrane stability.
|
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture.
Following decortication and graft placement to reconstruct the horizontal ridge deficiency, acellular dermal matrix (ADM) will be adapted to fully cover the augmented site with appropriate extension beyond the defect margins.
The ADM will be stabilized using titanium tacks and/or periosteal sutures as needed to ensure space maintenance and membrane stability.
|
|
Comparatore attivo: Guided Bone Regeneration with Resorbable Crosslinked Collagen Matrix (Mem-Lok) as a barrier
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture.
The graft will be contoured to reconstruct the horizontal ridge deficiency following decortication of the recipient site.
A resorbable collagen membrane [Mem-Lok® Resorbable Collagen Matrix (RCM) will be trimmed and positioned to fully cover the grafted area with extension beyond the defect margins and stabilized using titanium tacks and/or periosteal sutures as needed.
|
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture.
The graft will be contoured to reconstruct the horizontal ridge deficiency following decortication of the recipient site.
A resorbable collagen membrane [Mem-Lok® Resorbable Collagen Matrix (RCM) will be trimmed and positioned to fully cover the grafted area with extension beyond the defect margins and stabilized using titanium tacks and/or periosteal sutures as needed.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Horizontal ridge width gain
Lasso di tempo: baseline to 6 months
|
Horizontal ridge width gain (mm) at 6 months post-GBR (CBCT-based measurement) at 2mm and 4mm from the alveolar crest
|
baseline to 6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Soft tissue thickness change
Lasso di tempo: 9 months
|
Clinical assessment using an endodontic reamer and a calibrated periodontal probe
|
9 months
|
|
Patient centered outcomes using the Visual Analog Scale (VAS)
Lasso di tempo: 4 weeks
|
Patient centered outcomes including pain, bleeding, swelling, change in daily activities at 2 weeks and 4 weeks postoperatively, using the Visual Analog Scale (VAS)
|
4 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Maria L Geisinger, DDS, MS, University of Alabama at Birmingham
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB-300016808
- UAB Periodontology (Altro identificatore: University of Alabama at Birmingham)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Matrice dermica acellulare
-
International Centre for Diarrhoeal Disease Research...Completato
-
International Centre for Diarrhoeal Disease Research...Thrasher Research FundCompletato
-
IDRICompletatoDopo Kala Azar Dermal LeishmaniosiSudan